TY - JOUR
T1 - Chronic obstructive pulmonary disease
AU - Labaki, Wassim W.
AU - Rosenberg, Sharon R.
N1 - Funding Information:
American College of Physician The authors thank Michael R. Littner, MD, author of the previous version of this In the Clinic.
Publisher Copyright:
© 2020 American College of Physicians
PY - 2020/8/4
Y1 - 2020/8/4
N2 - Chronic obstructive pulmonary disease(COPD) is characterized by persistent respiratory symptoms and progressive airflow obstruction. Tobacco smoking is the leading cause but not the only one. A postbronchodilator FEV1–FVC ratio less than 0.70 is required for a diagnosis of COPD. Inhaler therapy is the backbone of treatment and should be complemented by a multifaceted management strategy that includes counseling and pharmacotherapy for smoking cessation, pulmonary rehabilitation, treatment of comorbidities, administration of influenza and pneumococcal immunizations, and prescription of long-term oxygen therapy in hypoxemic patients.
AB - Chronic obstructive pulmonary disease(COPD) is characterized by persistent respiratory symptoms and progressive airflow obstruction. Tobacco smoking is the leading cause but not the only one. A postbronchodilator FEV1–FVC ratio less than 0.70 is required for a diagnosis of COPD. Inhaler therapy is the backbone of treatment and should be complemented by a multifaceted management strategy that includes counseling and pharmacotherapy for smoking cessation, pulmonary rehabilitation, treatment of comorbidities, administration of influenza and pneumococcal immunizations, and prescription of long-term oxygen therapy in hypoxemic patients.
UR - http://www.scopus.com/inward/record.url?scp=85089041189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089041189&partnerID=8YFLogxK
U2 - 10.7326/AITC202008040
DO - 10.7326/AITC202008040
M3 - Article
C2 - 32745458
AN - SCOPUS:85089041189
SN - 0003-4819
VL - 173
SP - ITC17-ITC33
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 3
ER -